01:46 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; skin cancer Mouse studies suggest combining anti- PD-L1 therapies and promoters of reactive oxygen species (ROS) production or agonists of the mTOR or AMPK signaling pathways could help treat colorectal and skin...
07:00 , Oct 27, 2016 |  BC Innovations  |  Targets & Mechanisms

T cell gas, tumor brake

  A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α , to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Peroxisome proliferation-activated receptor-a (PPARA; PPARa) Mouse studies suggest PPARa agonists could help treat NSCLC. In transgenic mice that develop spontaneous...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

Tricor fenofibrate: Post-marketing study data

A meta-analysis of 45,058 patients in 18 placebo-controlled trials showed that fibrate therapy led to a 10% relative risk reduction of major cardiovascular events (p=0.048) and a 13% relative risk reduction for coronary events (p<0.0001)...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

CRx-401: Phase II data

Data from the double-blind, Canadian Phase II CRx-401-001 trial in 120 patients who are poorly controlled on metformin showed that CRx-401 plus metformin met the primary endpoint of significantly reducing fasting plasma glucose at day...
07:00 , Jun 1, 2009 |  BioCentury  |  Finance

Ebb & Flow

On its face, the deal to take out CuraGen Corp. (NASDAQ:CRGN) is returning about $0.18 for every dollar the genomics-based oncology company has raised since it went public. But the $94.5 million all-stock offer announced...
01:21 , May 28, 2009 |  BC Extra  |  Clinical News

CRx-401 meets diabetes endpoint

CombinatoRx Inc. (NASDAQ:CRXX) said CRx-401 plus metformin met the primary endpoint of significantly reducing fasting plasma glucose at day 90 compared to bezafibrate plus metformin in the Phase II CRx-401-001 trial to treat Type II...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Company News

CombinatoRx autoimmune, cancer, inflammation news

CombinatoRx restructured and reduced headcount across the company by about 50 (45%) to 90 to conserve cash. The company is seeking partners for its clinical compounds Synavive ( CRx-102 ), CRx-401, CRx-197 and CRx-191. Synavive,...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

Hepaconda: Phase IIa halted

Giaconda said it voluntarily suspended an Australian Phase IIa trial of Hepaconda in non-responding patients with HCV genotype 1 infection because normalization was not achieved and further formulation work is warranted. The company said data...
08:00 , Feb 7, 2008 |  BC Innovations  |  Targets & Mechanisms

PPAR-alpha's in cancer

In a paper published in the Proceedings of the National Academy of Sciences , Harvard University researchers demonstrated an anticancer effect in mice taking oral doses of the generic dyslipidemia drug fenofibrate. 1 The good...